This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre
by Zacks Equity Research
Abbott (ABT) forges ahead with initiatives to boost diabetes care. The latest CMS recognition will widen customer base for FreeStyle Libre glucose monitoring system.
After a Solid Start, What Awaits Dow ETF in Q4 Earnings?
by Sweta Killa
How will Dow ETF perform in Q4 Earnings?
Big Pharma CEOs Speak About Impact of Tax Reform on M&A
by Zacks Equity Research
This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
by Zacks Equity Research
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
by Zacks Equity Research
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Will J&J (JNJ) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.
Can AbbVie (ABBV) Stock Keep the Momentum Alive in 2018?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares are expected to be northbound in 2018, carrying on the momentum achieved last year.
Portola's (PTLA) AndexXa BLA Review Period Extended by FDA
by Zacks Equity Research
The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
Minerva Initiates Phase III Study on Schizophrenia Candidate
by Zacks Equity Research
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
Achillion's Renal Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.
Allergan's Vraylar Positive for Bipolar Disease in Phase III
by Zacks Equity Research
Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I depression. The trial meets its primary endpoints with significant progress in patients.
3 Low-Volatility ETFs for Your Portfolio
by Zacks Equity Research
Low-volatility ETFs might seem attractive to investors, as GOP Senate majority slims.
Pfizer's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Johnson & Johnson, ExxonMobil, American Airlines and Honda
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Top Analyst Reports for Microsoft, Johnson & Johnson & ExxonMobil
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Johnson & Johnson (JNJ) and ExxonMobil (XOM).
Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set
by Zacks Equity Research
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
JP Morgan Launches Minimum Volatility ETF
by Zacks Equity Research
JP Morgan rolls out minimum volatility US equity ETF.
Lilly Reports Mixed Results from Late-Stage Cyramza Study
by Zacks Equity Research
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi
by Zacks Equity Research
Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi.
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
by Arpita Dutt
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Sanofi Begins Combo Studies on Multiple Myeloma Candidate
by Zacks Equity Research
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
by Zacks Equity Research
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.